Genmab A/S (GNMSF)

198.11

0.00

(0.00%)

As of April 22 at 4:00:00 PM EDT. Market Open.

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from April 14 to April 18, 2025: Trading PlatformNo. of sharesAve

GlobeNewswire yesterday

GMAB

GNMSF
0.00%
GMAB or RGEN: Which Is the Better Value Stock Right Now?

GMAB vs. RGEN: Which Stock Is the Better Value Option?

Zacks 6 days ago

RGEN

GMAB.CO
Should Value Investors Buy Genmab (GMAB) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 7 days ago

GMAB.CO
Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025

Genmab (CPSE:GMAB) recently reported impressive first-quarter 2025 trade sales for DARZALEX, totaling USD 3,237 million, with strong performance both in the U.S. and internationally. Over the past week, the stock price increased by 1.93%, a movement aligned with broader market trends which saw a 6.8% rise. While Genmab's robust sales data for DARZALEX could have added weight to its market performance, the broader economic environment was influenced by tech and financial sectors leading U.S...

Simply Wall St. 7 days ago

GMAB

GNMSF
0.00%
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as repor

GlobeNewswire 8 days ago

GMAB

GNMSF
0.00%
Genmab A/S Share Capital Reduction

Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 12, 2025, it was decided to reduce the Company’s share capital with nominally DKK 2,076,853 by cancellation of 2,076,853 of the Company’s holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority. Genmab's share capital will be updated in Nasdaq's system as soon as possible and expe

GlobeNewswire 12 days ago

GMAB

GNMSF
0.00%
Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at whereGenmab A/S (NASDAQ:GMAB) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining […]

Insider Monkey 21 days ago

GMAB.CO
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; April 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genm

GlobeNewswire 21 days ago

GMAB

GNMSF
0.00%
Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade in […]

Insider Monkey 22 days ago

GMAB.CO
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

COPENHAGEN, Denmark, March 31, 2025--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is the first and only ADC to be granted European Union (EU) marketing authorization for people living with recurrent or metastatic ce

Business Wire 23 days ago

GMAB

GNMSF
0.00%
This drug company’s silver bullet is currently valued at zero

The scientists trying to find a cure for cancer know they have to be patient. Likewise, most shareholders who back companies at the forefront of these medical endeavours know they are playing the long game.

The Telegraph 23 days ago

GMAB.CO
Genmab’s Tivdak approved in Japan for advanced cervical cancer

The approval is based on open-label Phase III innovaTV 301 clinical trial data.

Pharmaceutical Technology 26 days ago

GMAB.CO

PFE
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. Tivdak is the first and only antibody-drug conjugate (ADC) to be approved for cervical cancer in Japan. The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK compared to chemotherapy in patients with advanced

Benzinga 26 days ago

GMAB.CO
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

COPENHAGEN, Denmark, March 27, 2025--Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan.

Business Wire 27 days ago

GMAB

GNMSF
0.00%
Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock Unit programCompletion expected no later than July 10, 2025 COPENHAGEN, Denmark; March 25, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program

GlobeNewswire 28 days ago

GMAB

GNMSF
0.00%
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously defend the company COPENHAGEN, Denmark; March 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today thatAbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US Co.; ProfoundBio (Suzhou) Co., Ltd.; and for

GlobeNewswire last month

GMAB

GNMSF
0.00%
Genmab A/S (GMAB): A Bull Case Theory

We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S (GMAB)’s share was trading at $20.20 as of March 18th. GMAB’s trailing and forward P/E were 11.41 and 11.61 respectively according to Yahoo Finance. Genmab (GMAB) is […]

Insider Monkey last month

GMAB.CO
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objective response rate (ORR) of 55.6% and median duration of response (mDOR) was not reached Phase 2 RAINFOLTM-01 and Phase 3 RAINFOLTM-02 trials evaluating the safety and efficacy of Rina-S at 120 mg/m2 in patients with platinum resistant ovarian cancer (PROC) are actively recruiting Genmab A/S (Nasdaq

GlobeNewswire last month

GMAB

GNMSF
0.00%
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company AnnouncementCOPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 12, 2025, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 13,926 restricted stock units to members of the Board of Directors and employees of the Company and the Company’s subsidiaries and 4,214 warrants to the employees of

GlobeNewswire last month

GMAB

GNMSF
0.00%
Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2024 Compensation Report was approvedSix members of the Board of Directors were re-electedDeloitte was re-elected as the auditor of the CompanyThe proposal from the Board of Directors to adopt amendments to the Remuneration Policy, the proposal on the Boa

GlobeNewswire last month

GMAB

GNMSF
0.00%

Performance Overview

Return	GNMSF	OMX Copenhagen 25 Index (^OMXC25)
YTD	-4.47%	--
1-Year	-31.61%	-17.26%
3-Year	-45.44%	-10.13%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Genmab A/S (GNMSF)

Transactions in Connection with Share Buy-back Program

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Should Value Investors Buy Genmab (GMAB) Stock?

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab A/S Share Capital Reduction

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

This drug company’s silver bullet is currently valued at zero

Genmab’s Tivdak approved in Japan for advanced cervical cancer

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Genmab A/S (GMAB): A Bull Case Theory

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting

Performance Overview